Infertility has become a pressing global health issue, affecting millions
of couples and driving the rapid growth of assisted reproductive technologies
(ART). As a key glycoprotein hormone, Human Chorionic Gonadotropin (HCG) plays
an irreplaceable role in ART—from triggering final oocyte maturation to
supporting luteal function and maintaining early pregnancy. With the global HCG
market projected to expand from $1.26 billion in 2024 to $1.34 billion in 2025
at a CAGR of 4.4% , the demand for high-purity, reliable HCG products is
soaring. For fertility clinics and pharmaceutical distributors, choosing a
supplier with advanced technology and strict quality control is critical to
ensuring clinical safety and treatment success.
Kangyuan, a leading biopharmaceutical enterprise specializing in
reproductive health, emerges as a trusted provider of Human Chorionic
Gonadotropin. Adhering to the concept of "purity for efficacy, precision for
fertility", Kangyuan adopts advanced recombinant DNA technology to produce HCG,
which fundamentally solves the problem of protein contaminants and oxidized
metabolites existing in traditional urine-derived HCG. The product strictly
complies with WHO international standards (including the 1st international
reference reagent 99/688 for intact HCG) and WHO GMP guidelines, ensuring each
batch is free from impurities and maintains consistent bioactivity.
Kangyuan’s Human Chorionic Gonadotropin features high specific bioactivity
and excellent clinical adaptability. By precisely controlling the recombinant
expression and purification process, the product retains the intact structure of
HCG, effectively stimulating luteinizing hormone receptors to trigger ovulation
and promote progesterone secretion. It undergoes multi-stage quality
inspections, including bioactivity assay, impurity analysis, and viral clearance
testing, to eliminate potential clinical risks. This high-purity HCG is widely
applicable to diverse ART scenarios, such as controlled ovarian hyperstimulation
cycles, luteal phase support, and treatment of male hypogonadism, meeting the
personalized needs of different patients.
With the Asia-Pacific region leading the growth of the global ART market,
Kangyuan leverages its strong production capacity and global logistics network
to provide stable HCG supply to partners in Southeast Asia, Europe, and other
regions. Backed by a professional R&D team, Kangyuan continuously optimizes
the production process to improve product stability and reduce the supply cycle,
helping partners seize market opportunities in the booming fertility drug
sector. The company also offers comprehensive after-sales services, including
clinical technical guidance and product specification consulting, to solve
practical problems for global cooperative institutions.
Whether you are a fertility clinic, pharmaceutical distributor, or research
institution, Kangyuan provides customized cooperation solutions tailored to your
specific needs—from flexible supply plans to professional technical training.
For inquiries about Human Chorionic Gonadotropin product specifications,
production capacity, or cooperation opportunities, please contact us directly.
Let’s join hands to leverage high-purity HCG products to advance global
fertility care and bring hope to more couples struggling with infertility.